An unsolicited bid by private equity group CVC to take control of Italian pharma company Recordati looks likely to come off, ...

Biogen and Denali have now confirmed that the results show BIIB122 (also known as DNL151) did not slow the progression of ...

DPP1 inhibitor Brinsupri (brensocatib), given as a once-daily oral tablet, became the first therapy approved by the FDA for ...

Two months after saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement ...

A phase 2 trial of Sanofi's experimental therapy for alpha-1 antitrypsin deficiency (AATD) has raised the hope of an ...

Bayer has filed to modify the label for its chronic kidney disease (CKD) Kerendia to include people with type 1 diabetes, ...

Last year, Novo Nordisk accused Singapore-based biotech KBP of concealing clinical data ahead of a $1.3 billion licensing ...

The phase 3 trial was evaluating two doses of anti-LAG-3 antibody fianlimab in combination with PD-1 inhibitor Libtayo ...

The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola that is causing ...

The 42-subject pilot study compared three weeks of treatment with Remepy's lead product candidate Hybridopa – which consists ...

Eli Lilly's triple G agonist retatrutide has achieved weight loss of more than 28% in a new phase 3 trial that keeps it on course for regulatory filings later this year. The readout from the TRIUMPH-1 ...

Embattled UK Prime Minister Sir Keir Starmer has put changes to the health service on the legislative programme in today's ...